RxDoctor Payments DataLook up a doctor →

Bibhu Mohanty, MD

Interventional Cardiology · Tampa, FLNPI 1720246242

Payments from drug & device makers

$303,700in general payments, 2019–2025

Across 547 payments — averaging $555.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$149K
  • W. L. Gore & Associates, Inc.$88K
  • Medtronic$28K
  • Gentuity, LLC$13K
  • Abbott$11K
  • Philips North America LLC$3K
  • plus $10K from 21 others
$2,000in research payments, 2019–2025

Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$2K

What the payments were for

  • Consulting fees$77,71345%
  • Speaking & faculty fees$40,09023%
  • Travel & lodging$25,73315%
  • Food & beverage$27,63716%
  • Entertainment$130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$303,700 in reported general payments places this provider in the 90th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$164,918
Medicare patients
426
Services billed
835

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$79,386
Repatha SureclickEvolocumab36$45,866
XareltoRivaroxaban47$41,317
EntrestoSacubitril/Valsartan23$35,429
Praluent PenAlirocumab12$13,339
Metoprolol Succinate130$2,371
Ranolazine ErRanolazine19$2,061
Atorvastatin Calcium102$1,054
ClopidogrelClopidogrel Bisulfate77$1,012
Carvedilol75$769
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide13$768
Rosuvastatin Calcium81$521
Amlodipine Besylate72$513
Pravastatin Sodium14$498
Valsartan22$494

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →